A Multicenter, Randomized, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of DWP16001 as add-on Therapy to Drug A, With or Without Antihyperglycemic Drugs, in Patients With Type 2 Diabetes Mellitus
Latest Information Update: 10 Apr 2024
At a glance
- Drugs Enavogliflozin (Primary) ; Antihyperglycaemics
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms ENHANCE-I
- Sponsors Daewon Pharmaceutical
Most Recent Events
- 05 Apr 2024 Planned number of patients changed from 188 to 240.
- 05 Apr 2024 Planned End Date changed from 30 Apr 2024 to 30 Sep 2024.
- 05 Apr 2024 Planned primary completion date changed from 30 Apr 2024 to 30 Sep 2024.